US20080064099A1 - Isolation of Inner Cell Mass for the Establishment of Human Embryonic Stem Cell (hESC) Lines - Google Patents

Isolation of Inner Cell Mass for the Establishment of Human Embryonic Stem Cell (hESC) Lines Download PDF

Info

Publication number
US20080064099A1
US20080064099A1 US11/939,397 US93939707A US2008064099A1 US 20080064099 A1 US20080064099 A1 US 20080064099A1 US 93939707 A US93939707 A US 93939707A US 2008064099 A1 US2008064099 A1 US 2008064099A1
Authority
US
United States
Prior art keywords
cell mass
inner cell
blastocyst
cells
aperture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/939,397
Inventor
Firuza Parikh
Satish Totey
Shailaja Saxena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliance Life Sciences Pvt Ltd
Original Assignee
Reliance Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliance Life Sciences Pvt Ltd filed Critical Reliance Life Sciences Pvt Ltd
Priority to US11/939,397 priority Critical patent/US20080064099A1/en
Publication of US20080064099A1 publication Critical patent/US20080064099A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42Gynaecological or obstetrical instruments or methods
    • A61B17/425Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/435Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser

Definitions

  • the present invention relates to a method of isolation of inner cell mass (ICM) derived from blastocyst stage mammalian embryo for establishing human embryonic stem cell (hESC) lines, using a non-contact diode laser technique.
  • ICM inner cell mass
  • hESC human embryonic stem cell
  • Embryonic stem (ES) cells are the special kind of cells that can both duplicate themselves (self renew) and produce differentiated functionally specialized cell types. These stem cells are capable of becoming almost all of the specialized cells of the body and thus, may have the potential to generate replacement cells for a broad array of tissues and organs such as heart, pancreas, nervous tissue, muscle, cartilage and the like.
  • Stem cells have the capacity to divide and proliferate indefinitely in culture.
  • Scientists use these two properties of stem cells to produce seemingly limitless supplies of most human cell types from stem cells, paving the way for the treatment of diseases by cell replacement.
  • cell therapy has the potential to treat any disease that is associated with cell dysfunction or damage including stroke, diabetes, heart attack, spinal cord injury, cancer and AIDS.
  • the potential of manipulation of stem cells to repair or replace diseased or damaged tissue has generated a great deal of excitement in the scientific, medical and/biotechnology investment communities.
  • ES cells from various mammalian embryos have been successfully grown in the laboratory. Evans and Kaufman (1981) and Martin (1981) showed that it is possible to derive permanent lines of embryonic cells directly from mouse blastocysts. Thomson et al. (1995 and 1996) successfully derived permanent cell lines from rhesus and marmoset monkeys.
  • Pluripotent cell lines have also been derived from pre-implantation embryos of several domestic and laboratory animal species such as bovines (Evans et al., 1990) Porcine (Evans et al., 1990, Notarianni et al., 1990), Sheep and goat (Meinecke-Tillmann and Whycke, 1996, Notarianni et al., 1991), rabbit (Giles et al., 1993, Graves et al., 1993) Mink (Sukoyan et al., 1992) rat (Iannaccona et al., 1994) and Hamster (Doetschman et al., 1988). Recently, Thomson et al (1998) and Reubinoff et al (2000) have reported the derivation of human ES cell lines. These human ES cells resemble the rhesus monkey ES cell lines.
  • ES cells are found in the ICM of the human blastocyst, an early stage of the developing embryo lasting from the 4th to 7th day after fertilization.
  • the blastocyst is the stage of embryonic development prior to implantation that contains two types of cells viz.
  • Trophectoderm outer layer which gives extra embryonic membranes.
  • ICM Inner cell mass
  • ES cells disappear after the 7th day and begin to form the three embryonic tissue layers.
  • ES cells extracted from the ICM during the blastocyst stage can be cultured in the laboratory and under the right conditions proliferate indefinitely.
  • ES cells growing in this undifferentiated state retain the potential to differentiate into cells of all three enthryonic tissue layers.
  • the cells of the inner cell mass give rise to all the embryonic tissues. It is at this stage of embryogenesis, near the end of first week of development, that ES cells can be derived from the ICM of the blastocyst.
  • blastocyst is allowed to hatch naturally after plating on the feeder layer.
  • the hatching of the blastocyst usually takes place on day 6.
  • the inner cell mass (ICM) of the hatched blastocyst develops an outgrowth. This outgrowth is removed mechanically and is subsequently grown for establishing embryonic stem cell lines.
  • ICM inner cell mass
  • this procedure has few disadvantages.
  • trophectoderm cells proliferate very fast in the given culture conditions and many times, suppress the outgrowth of inner cell mass.
  • Third, the percentage of blastocysts hatching spontaneously in humans is very low.
  • microsurgery Another method of isolation of inner cell mass is mechanical aspiration called microsurgery.
  • the blastocyst is held by the holding pipette using micromanipulator system and positioned in such a way that the inner cells mass (ICM) is at 9 o'clock position.
  • the inner cell mass (ICM) is aspirated using a bevel-shaped biopsy needle and is inserted into the blastocoel cavity.
  • This procedure too is disadvantageous as the possibility to isolate the complete inner cell mass is low and many times cells get disintegrated. It is a very tedious procedure and may cause severe damage to the embryo.
  • the operation at the cellular level requires tools with micrometer precision, thereby minimizing damage and contamination.
  • Immunosurgery a commonly used procedure to isolate inner cell mass (ICM).
  • the inner cell mass (ICM) is isolated by complement mediated lysis.
  • the blastocyst is exposed either to acid tyrode solution or pronase enzyme solution in order to remove the zona pellucida (shell) of blastocyst.
  • the zona free embryo is then exposed to human surface antibody for about 30 min to one hour. This is followed by exposure of embryos to guinea pig complement in order to lyse the trophectoderm.
  • the complement mediated lysed trophectoderm cells are removed from inner cell mass (ICM) by repeated mechanical pipetting with a finely drawn Pasteur pipette.
  • the human cell lines studied to date are mainly derived by using a method of immunosurgery, where animal based antisera and complement was used.
  • feeder cells for culturing the human embryonic stem cell (hESC) lines produces mixed cell population that require the Embryonic stem cells (ESC) to be separated from feeder cell components and this impairs scale up.
  • ESC Embryonic stem cells
  • Geron established a procedure where human Embryonic Stem Cell (hESC) line was cultured in the absence of feeder cells (XU et.al 2001).
  • the hESC were cultured on an extracellular matrix in a conditioned medium and expanded in this growth environment in an undifferentiated state.
  • the hESC contained no xenogenic components of cancerous origin from other cells in the culture.
  • the production of hESC cells and their derivatives were more suited for commercial production. In this process, there was no need to produce feeder cells on an ongoing basis to support the culture, and the passaging of cells could be done mechanically.
  • the inner cell mass (ICM) is isolated by immunosurgery method, wherein the initial derivation of Embryonic Stem Cells is carried out using feeder layer containing xenogenic components. This raises the issue of possible contamination with animal origin viruses and bacteria.
  • Er:YAG laser was used to thin the ZP of embryos derived from patients undergoing repeated IVF.
  • embryologists are able to achieve accurate reduction of the ZP by 50%, which is very difficult with acidic Tyrode's solution. Presence of Acid Tyrode's solution near the embryo may also be detrimental.
  • the rate of clinical pregnancies in the laser-hatched group was 42.7%, as compared to 23.1% in the control unhatched group. Since this data looked promising, the indication of laser-assisted hatching was extended. Women undergoing IVF for the first time yielded 39.6% clinical pregnancy rate in the laser-treated group versus a 19% rate in the control unhatched group (Parikh et al 1996).
  • ICM inner cell mass
  • the present invention involves the isolation of inner cell mass (ICM), using laser ablation technique without undergoing the cumbersome procedure of immunosurgery. Hence, in the present invention, the use of animal derived antibodies or sera are eliminated and the procedure is safe, simple, rapid, and commercially viable.
  • ICM inner cell mass
  • the present invention obviates the shortcomings associated with the conventional methods of isolation of inner cell mass (ICM).
  • the inner cell mass (ICM) isolated by the present invention is found to be intact without causing any destruction or damage to the cells.
  • the present invention thus provides a quick reliable and non-invasive method for isolation of inner cell mass (ICM). It also completely ruptures the trophectoderm thereby minimizing the contamination of inner cell mass (ICM), thus ensuring the purity of inner cell mass (ICM).
  • the present invention relates to isolation of inner cell mass, using laser ablation of zona pellucida (ZP) and trophectoderm (TE) and aspiration of inner cell mass for establishing embryonic stem cell lines.
  • the non contact diode laser used is highly accurate and reliable tool for cellular microsurgery.
  • the system incorporates the latest in fiber optic technology to provide the most compact laser system currently available.
  • the 1.48 .mu.m diode non-contact Saturn Laser System is mounted/implanted via the epifluorescence port to inverted microscope fitted with micromanipulators.
  • a pilot laser is used to target the main ablation laser and a series of LEDs inform the user when the laser is primed and is ready to fire.
  • a two-second-operation window is used to reduce the possibility of accidentally firing the laser.
  • the spot diameter of the laser can be varied according to the hole size required.
  • Couples undergoing in vitro fertilization (IVF) treatment voluntarily donate surplus human embryos. These embryos are used for research purposes after taking the written, voluntary consent from these couples.
  • blastocyst stage embryos are taken for the isolation of inner cell mass.
  • the blastocyst is placed in a 35 mm petridish in a 50 micro litre droplets of Ca++/Mg++ free embryo biopsy medium and is covered with mineral oil.
  • the micromanipulator is set up to perform the embryo biopsy procedure.
  • the blastocyst is placed in embryo biopsy medium and the petridish containing the blastocyst is placed on the heating stage of the microscope.
  • the blastocyst is positioned at the center of the field.
  • the blastocyst is immobilized on to the holding pipette in such a way that the inner cell mass is at 3 o'clock position.
  • the zona pellucida and trophectoderm close to inner cell mass is positioned on the aiming spot of the laser beam.
  • a small portion of zona pellucida and trophectoderm is laser ablated.
  • Biopsy pipette is then gently inserted through the hole in the zona pellucida and trophectoderm and the inner cell mass is gently aspirated.
  • the cells are given several washes with embryonic stem cell (ESC) medium.
  • the cells are then plated on to feeder layer with embryonic stem cell medium for establishing embryonic stem cell lines.
  • ESC embryonic stem cell
  • the embryonic stem cells were then characterized for cell surface markers such as SSEA-1, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, OCT-4 and alkaline phosphatase.
  • the embryonic stem cell lines are also karyotyped.
  • Protocol generally used for infertility patients for obtaining viable embryo is as follows:
  • the ovarian superovulation began with gnRH agonist analog suppression daily starting in the mid-luteal phase and administered in doses of 500-900 mgs for about 9-12 days.
  • Ovarian stimulation was started after adequate ovarian suppression with human menopausal gonadotropins (hMG) or recombinant follicle stimulating hormone (FSH) (Gonal-F, Recagon) in appropriate doses depending on the age and ovarian volume. The dose was also adjusted as necessary to produce controlled ovarian stimulation.
  • Serum beta-estradiol (E2) measurements were carried out as required. Vaginal ultrasound was performed daily from cycle day 7 onward. Human Chorionic gonadotropin 5000-10000 I.U. was administered when three or more follicles were at least 17 mm in largest diameter. Transvaginal aspiration was performed 34-36 h later. Oocytes were then subjected to intracytoplasmic sperm injection.
  • a glass holding pipette 40-60 .mu.m in diameter was used to secure the egg. Motile sperm were placed in a drop of polyvinyl pyrolidone (PVP) solution and overlaid with mineral oil. An injection needle with an outer diameter of roughly 5-6 ⁇ m and inner diameter 3-4 ⁇ m was used to pierce the zona pellucida at about 3 o'clock position. The selected spermatozoon was immobilized by cutting the tail with the injection micropipette. The holding pipette secured the oocyte and spermatozoon was injected directly into the center of the oocyte.
  • PVP polyvinyl pyrolidone
  • Oocytes were checked after 16-18 hours of culture for fertilization. At this point the fertilized oocyte had pro-nuclei (also called one cell embryo).
  • pro-nuclei also called one cell embryo.
  • One-cell embryos were then transferred into pre-equilibrated fresh ISM-1 medium and incubated at 37° C. in a 5% CO 2 in air. The next day embryos were transferred into ISM-2 medium. Every alternate day embryos were transferred into fresh ISM-2 medium. From day 5 onward embryos were checked for the blastocyst development. After the treatment is over, the surplus blastocysts were donated by the couples for this research work.
  • the present invention relates to describing a unique method for inner cell mass isolation for establishment of embryonic stem cells using the non-contact diode laser.
  • the laser is highly accurate and reliable tool for cellular microsurgery.
  • the system incorporates the latest in fiber optic technology to provide the most compact laser system currently available.
  • the 1.48 ⁇ m diode non-contact Saturn Laser System was mounted via the epifluorescence port to Zeiss inverted microscope fitted with micromanipulators.
  • a pilot laser was used to target the main ablation laser and a series of LED's, inform the user when the laser is primed and ready to discharge the laser beam.
  • a two-second-operation window was used to reduce the possibility of accidentally firing the laser.
  • the spot diameter of the laser can be varied according, to the ablation size required.
  • the blastocyst stage embryo was individually placed in a 50 ⁇ l drop of biopsy medium (Ca ++ /Mg ++ free) in a 35-mm petri dish.
  • the embryo was immobilized on to the holding pipette in such a way that the inner cell mass remained at 3 o'clock position and the zona pellucida and trophectoderm close to inner cell mass positioned on the aiming spot.
  • a continuous 1.48 ⁇ m diode laser was used to aperture the Zona Pellucida (ZP), which is a glycoprotein layer protecting the oocyte. At this wavelength, the hole was induced by a local thermo-dissolution of the glycoprotein matrix.
  • ZP Zona Pellucida
  • trophectoderm cells were ablated by giving 3 pulses to cause photolysis. After ablation of both zona pellucida and trophectoderm, the aspiration pipette was introduced through laser-ablated hole and ICM was removed by gentle aspiration, having an internal diameter of 30-35 microns.
  • Embryonic fibroblast feeder layer was preferably obtained from 12.5 to 13.5 day old C57BL/6 mice or C57L/6XSJL F-1 mice or out bred CD1 mice or from human amniotic fluid-and used as a feeder layer. Embryonic fibroblast feeder layer was inactivated by gamma irradiation (3500 rads).
  • the mouse embryonic fibroblast feeder layer was cultured on 0.5% gelatin coated plate with ES medium consisting of Dulbecco's modified Eagle's medium without Sodium pyruvate with high glucose contain (70-90%), Fetal bovine serum (10-30%), beta-mercaptoethanol (0.1 mM), non-essential amino acids (1%), L-Glutamine 2 mM, basic fibroblast growth factor (4 ng/ml). Inner cell mass was then plated on mouse inactivated embryonic fibroblast. After 4-7 days, ICM derived masses were removed from outgrowth with sterile fire polished pipette and were dissociated mechanically and plated on fresh feeder cells. Further dissociation was carried out with 0.5% trypsin-EDTA supplemented with 1% chicken serum.
  • Established cell lines were karyotyped and characterized for several surface markers such as SSEA-1, SSEA-3, SSEA-4, OCT-4, Alkaline phosphatase, TRA-1-81, TRA-1-60 as described by Thomson et al., (1998), Reubinoff et al., (2000).
  • blastocyst stage human embryos were used for the isolation of inner cell mass. Embryos were washed several times in blastocyst culture medium (ISM-2 medium, Medicult, Denmark). Individual blastocyst was then placed in the 50 ⁇ l drop of Ca++/Mg++ free embryo biopsy medium (EB 10 medium, Scandinavian). Micro drops were covered with mineral oil. Micromanipulator was set up. A glass holding pipette with outer diameter 75 ⁇ m and inner diameter 15 ⁇ m was used to secure the embryo. Biopsy pipette with an outer diameter of roughly 49 ⁇ m and inner diameter 35 ⁇ m was used for aspiration of inner cell mass. A pilot laser was used to target the main ablation laser.
  • Embryo was immobilized on to the holding pipette in such a way that inner cell mass remained at 3 o'clock position and the zona pellucida and trophectoderm close to inner cell mass positioned to the aiming spot.
  • the hole was induced by a local thermo-dissolution of the zona.
  • Trophectoderm cells were ablated by giving 3 pulses to cause photolysis.
  • the biopsy pipette was introduced through laser ablated hole and inner cell mass was removed. Inner cell mass was then washed several times in ES medium and placed in 96 well dish in the presence or absence of feeder cells. The following data is presented in the tabular form.
  • the objective was to determine efficiency of isolation of inner cell mass with conventional method, i.e. immunosurgery, and compared with newly invented laser ablated method.
  • blastocyst stage human embryos were used for isolation of inner cell mass. Embryos were washed several times with blastocyst culture medium (ISM-2 medium) and followed by ES medium. Individual blastocyst stage embryo was then placed in 50 ⁇ l microdrops of 1:50 anti-human antibody (Sigma) for 30 minutes at 37° C. and 5% CO 2 in air. Blastocyst stage embryos were then washed four times after incubation with ES medium. Blastocysts were then again placed in 50 ⁇ l of microdrops of guinea pig complement at the concentration of 1:10 for 10 minutes at 37° C. and 5% CO 2 in air.
  • ISM-2 medium blastocyst culture medium
  • ES medium blastocyst culture medium
  • Individual blastocyst stage embryo was then placed in 50 ⁇ l microdrops of 1:50 anti-human antibody (Sigma) for 30 minutes at 37° C. and 5% CO 2 in air.
  • FIG. 1 ( a ) to 1 ( g ) of the present invention pertains to the isolation of inner cell mass (ICM) from the blastocyst of one embryo and FIG. 2 ( a ) to 2 ( g ) pertains to the isolation of inner cell mass (ICM) from the blastocyst of another embryo.
  • FIGS. 3, 4 , and 5 pertains to culturing of ICM on feeder cells at different stages.
  • FIG. 1 ( a ) is a scanned image of human blastocyst, secured with glass holding pipette such that the ICM is at 3 o'clock position.
  • FIG. 1 ( b ) is a scanned image wherein part of zona pellucida and trophectoderm ablated with laser (arrow).
  • FIG. 1 ( c ) is a scanned image of aspiration pippette close to the blastocyst following zona and trophectoderm ablation.
  • FIG. 1 ( d ) is a scanned image of beginning of aspiration of ICM with aspiration pipette.
  • FIG. 1 ( e ) is a scanned image of large portion of ICM in the aspiration pipette during aspiration process.
  • FIG. 1 ( f ) is a scanned image of the ICM after removing from the blastocyst.
  • FIG. 1 ( g ) is a scanned image of the remaining trophectoderm and zona pellucida remaining after ICM isolation.
  • FIG. 2 ( a ) is a scanned image of another human blastocyst, secured with glass holding pipette such that the ICM is at 3 o'clock position.
  • FIG. 2 ( b ) is a scanned image of slight protrusion of inner cell mass after zona and trophectoderm is laser ablated.
  • FIG. 2 ( c ) is a scanned image of the aspiration pipette being position close to the ICM after ablating the zona and neighboring trophectoderm cells with laser.
  • FIG. 2 ( d ) is a scanned image of ICM being aspirated with the aspiration pipette by gentle suction.
  • FIG. 2 ( e ) is a scanned image of large portion of ICM in the aspiration pipette.
  • FIG. 2 ( f ) is a scanned image of the ICM after removing from the blastocyst.
  • FIG. 2 ( g ) is a scanned image of the trophectoderm and zona pellucida left after the isolation of ICM from the blastocyst.
  • FIG. 3 ( a ) is a scanned image of isolated inner cell mass in culture seeded on primary mouse embryonic fibroblast feeder cells (day 3).
  • FIG. 3 ( b ) is a scanned image of isolated inner cell mass in culture on primary mouse embryonic fibroblast feeder cells (day 7).
  • FIG. 4 is a scanned image of isolated ICM in culture on the primary mouse embryonic fibroblast feeder cells (day 5) another embryo.
  • FIG. 5 is a scanned image of embryonic stem cell line derived from inner cell mass isolated by laser ablation method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Optics & Photonics (AREA)
  • Electromagnetism (AREA)
  • Otolaryngology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

A method of establishing a cell line from the inner cell mass of a blastocyst, comprising: isolating a blastocyst having a zona pellucida, a trophectoderm, and an inner cell mass; creating an aperture in the blastocyst by laser ablation; isolating cells from the inner cell mass from the blastocyst through the aperture; and culturing the cells to establish a cell line, wherein the cells are cultured under feeder free conditions.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application is a divisional application of U.S. application Ser. No. 10-226,711, filed Aug. 23, 2002, U.S. Pat. No. 7,294,508, which claims the benefit of priority of U.S. Provisional Application Ser. No. 60/314,323 filed on Aug. 23, 2001, the disclosures of both of which are incorporated herein in their entirety by reference for all purposes.
  • FIELD OF THE INVENTION
  • The present invention relates to a method of isolation of inner cell mass (ICM) derived from blastocyst stage mammalian embryo for establishing human embryonic stem cell (hESC) lines, using a non-contact diode laser technique.
  • BACKGROUND OF THE INVENTION
  • The isolation of human stem cells offers the promise of a remarkable array of novel therapeutics. Biologic therapies derived from such cells through tissue regeneration and repairs as well as through targeted delivery of genetic material are expected to be effective in the treatment of a wide range of medical conditions. Efforts to analyze and assess the safety of using human stem cells in the clinical setting are vitally important to this endeavor.
  • Embryonic stem (ES) cells are the special kind of cells that can both duplicate themselves (self renew) and produce differentiated functionally specialized cell types. These stem cells are capable of becoming almost all of the specialized cells of the body and thus, may have the potential to generate replacement cells for a broad array of tissues and organs such as heart, pancreas, nervous tissue, muscle, cartilage and the like.
  • Stem cells have the capacity to divide and proliferate indefinitely in culture. Scientists use these two properties of stem cells to produce seemingly limitless supplies of most human cell types from stem cells, paving the way for the treatment of diseases by cell replacement. In fact, cell therapy has the potential to treat any disease that is associated with cell dysfunction or damage including stroke, diabetes, heart attack, spinal cord injury, cancer and AIDS. The potential of manipulation of stem cells to repair or replace diseased or damaged tissue has generated a great deal of excitement in the scientific, medical and/biotechnology investment communities.
  • ES cells from various mammalian embryos have been successfully grown in the laboratory. Evans and Kaufman (1981) and Martin (1981) showed that it is possible to derive permanent lines of embryonic cells directly from mouse blastocysts. Thomson et al. (1995 and 1996) successfully derived permanent cell lines from rhesus and marmoset monkeys. Pluripotent cell lines have also been derived from pre-implantation embryos of several domestic and laboratory animal species such as bovines (Evans et al., 1990) Porcine (Evans et al., 1990, Notarianni et al., 1990), Sheep and goat (Meinecke-Tillmann and Meinecke, 1996, Notarianni et al., 1991), rabbit (Giles et al., 1993, Graves et al., 1993) Mink (Sukoyan et al., 1992) rat (Iannaccona et al., 1994) and Hamster (Doetschman et al., 1988). Recently, Thomson et al (1998) and Reubinoff et al (2000) have reported the derivation of human ES cell lines. These human ES cells resemble the rhesus monkey ES cell lines.
  • ES cells are found in the ICM of the human blastocyst, an early stage of the developing embryo lasting from the 4th to 7th day after fertilization. The blastocyst is the stage of embryonic development prior to implantation that contains two types of cells viz.
  • 1. Trophectoderm: outer layer which gives extra embryonic membranes.
  • 2. Inner cell mass (ICM): which forms the embryo proper.
  • In normal embryonic development, ES cells disappear after the 7th day and begin to form the three embryonic tissue layers. ES cells extracted from the ICM during the blastocyst stage, however, can be cultured in the laboratory and under the right conditions proliferate indefinitely. ES cells growing in this undifferentiated state retain the potential to differentiate into cells of all three enthryonic tissue layers. Ultimately, the cells of the inner cell mass give rise to all the embryonic tissues. It is at this stage of embryogenesis, near the end of first week of development, that ES cells can be derived from the ICM of the blastocyst.
  • The ability to isolate ES cells from blastocysts and grow them in culture seems to depend in large part on the integrity and condition of the blastocyst from which the cells are derived. In short, the blastocyst that is large and has distinct inner cell mass tends to yield ES cells most efficiently. Several methods have been used for isolation of inner cell mass (ICM) for the establishment of embryonic stem cell lines. The most common methods are as follows:
  • 1. Natural Hatching of the Blastocyst:
  • In this procedure blastocyst is allowed to hatch naturally after plating on the feeder layer. The hatching of the blastocyst usually takes place on day 6. The inner cell mass (ICM) of the hatched blastocyst develops an outgrowth. This outgrowth is removed mechanically and is subsequently grown for establishing embryonic stem cell lines. However, this procedure has few disadvantages. First, trophectoderm cells proliferate very fast in the given culture conditions and many times, suppress the outgrowth of inner cell mass. Second, while removing the outgrowth of the inner cell mass mechanically, there is a chance of isolating trophectoderm cells. Third, the percentage of blastocysts hatching spontaneously in humans is very low.
  • 2. Microsurgery:
  • Another method of isolation of inner cell mass is mechanical aspiration called microsurgery. In this process, the blastocyst is held by the holding pipette using micromanipulator system and positioned in such a way that the inner cells mass (ICM) is at 9 o'clock position. The inner cell mass (ICM) is aspirated using a bevel-shaped biopsy needle and is inserted into the blastocoel cavity. This procedure too is disadvantageous as the possibility to isolate the complete inner cell mass is low and many times cells get disintegrated. It is a very tedious procedure and may cause severe damage to the embryo. The operation at the cellular level requires tools with micrometer precision, thereby minimizing damage and contamination.
  • 3. Immunosurgery:
  • Immunosurgery a commonly used procedure to isolate inner cell mass (ICM). The inner cell mass (ICM) is isolated by complement mediated lysis. In this procedure, the blastocyst is exposed either to acid tyrode solution or pronase enzyme solution in order to remove the zona pellucida (shell) of blastocyst. The zona free embryo is then exposed to human surface antibody for about 30 min to one hour. This is followed by exposure of embryos to guinea pig complement in order to lyse the trophectoderm. The complement mediated lysed trophectoderm cells are removed from inner cell mass (ICM) by repeated mechanical pipetting with a finely drawn Pasteur pipette. All the embryonic stem cell lines reported currently in the literature have been derived by this method. However, this method has several disadvantages. First the embryo is exposed for a long time to acid tyrode or pronase causing deleterious effects on embryo, thereby reducing the viability of embryos. Second, it is a time consuming procedure as it takes about 1.5 to 2.0 hours. (Narula et al., 1996). Third, the yield of inner cell mass (ICM) per blastocyst is low. Fourth, critical storage conditions are required for antibody and complement used in the process. Last, it involves the risk of transmission of virus and bacteria of animal origin to humans, as animal derived antibodies and complement are used in the process. In this process, two animal sera are used. One is rabbit antihuman antiserum and the other is guinea pig complement sera.
  • The human cell lines studied to date are mainly derived by using a method of immunosurgery, where animal based antisera and complement was used.
  • Other possible disadvantages of the existing cell lines are as follows:
  • 1. Use of feeder cells for culturing the human embryonic stem cell (hESC) lines produces mixed cell population that require the Embryonic stem cells (ESC) to be separated from feeder cell components and this impairs scale up.
  • 2. Embryonic stem cells (ESC) get contaminated by transcripts from feeder cells and cannot be used on a commercial scale. It can be used only for research purposes.
  • Geron established a procedure where human Embryonic Stem Cell (hESC) line was cultured in the absence of feeder cells (XU et.al 2001). The hESC were cultured on an extracellular matrix in a conditioned medium and expanded in this growth environment in an undifferentiated state. The hESC contained no xenogenic components of cancerous origin from other cells in the culture. Also, the production of hESC cells and their derivatives were more suited for commercial production. In this process, there was no need to produce feeder cells on an ongoing basis to support the culture, and the passaging of cells could be done mechanically. However, the main disadvantage of this procedure is that the inner cell mass (ICM) is isolated by immunosurgery method, wherein the initial derivation of Embryonic Stem Cells is carried out using feeder layer containing xenogenic components. This raises the issue of possible contamination with animal origin viruses and bacteria.
  • In order to simplify the procedure of inner cell mass isolation and to make it safe, the scientists of the present invention have come out with a novel method of isolation of the inner cell mass using a non-contact laser, wherein, the use of animal based antisera and complement have been eliminated.
  • Use of Laser Technique in Assisted Reproduction:
  • With the advent of assisted reproductive technologies (ART), several methods have been used for improving fertilization, facilitating blastocyst hatching (Cohen et al, 1990) and performing blastomere biopsy (Tarin and Handyside, 1993). Commonly used methods are chemical (Gordon and Talansky 1986), mechanical (Depypere et al., 1988) and laser (Feichtinger et al., 1992) so as to produce holes in the zona pellucida (Gordon, 1988). Recently, an infrared 1.48 μm diode laser beam focused through a microscope objective was shown to allow rapid, easy and non-touch microdrilling of mouse and human zona pellucida and high degree of accuracy was maintained under conventional culture conditions (Rink et al., 1994). The drilling effect was shown due to a highly localized heat-dependent disruption of the zona pellucida glycoprotein matrix (Rink et al., 1996). Contrary to the detrimental effect on compacted mouse embryos induced by the 308 nm xenon-chlorine excimer laser (Neev et al., 1993), the drilling process in the infrared region did not affect embryo survival in mice (Germond et al., 1995) or in humans (Antinori et al., 1994).
  • Currently, lasers are being investigated as a tool to aid fertilization and in assisted hatching. Recent reports show that use of 1.48 μm diode laser for microdrilling mouse zona pellucida is highly safe and does not affect neuro-anatomical and neurochemical properties in mice and also improves fertilization (Germond et al., 1996). Obruca and colleagues first reported the success of laser-assisted hatching in human IVF in 1994. In this study, a 20- to 30-micron hole was made in the zona pellucida (ZP) when the embryos were at the two- to four-cell stage, and embryos were transferred immediately. Patients with previous IVF failures from two separate centers were included in this study. There was a higher implantation rate per embryo in the laser-assisted hatching group (14.4%) versus the control group (6%). Pregnancy rates per transfer were also improved (40% versus 16.2%).
  • In a separate study, Er:YAG laser was used to thin the ZP of embryos derived from patients undergoing repeated IVF. Using a laser for thinning the ZP, embryologists are able to achieve accurate reduction of the ZP by 50%, which is very difficult with acidic Tyrode's solution. Presence of Acid Tyrode's solution near the embryo may also be detrimental. The rate of clinical pregnancies in the laser-hatched group was 42.7%, as compared to 23.1% in the control unhatched group. Since this data looked promising, the indication of laser-assisted hatching was extended. Women undergoing IVF for the first time yielded 39.6% clinical pregnancy rate in the laser-treated group versus a 19% rate in the control unhatched group (Parikh et al 1996).
  • During the last decade there has been ongoing research on the isolation of inner cell mass (ICM), as it is useful in establishing embryonic stem cell lines which in turn have the ability to develop into most of the specialized cells in the human body including blood, skin, muscle and nerve cells. They also have the capacity to divide and proliferate indefinitely in culture.
  • The present invention involves the isolation of inner cell mass (ICM), using laser ablation technique without undergoing the cumbersome procedure of immunosurgery. Hence, in the present invention, the use of animal derived antibodies or sera are eliminated and the procedure is safe, simple, rapid, and commercially viable.
  • The present invention, obviates the shortcomings associated with the conventional methods of isolation of inner cell mass (ICM). The inner cell mass (ICM) isolated by the present invention is found to be intact without causing any destruction or damage to the cells. The present invention thus provides a quick reliable and non-invasive method for isolation of inner cell mass (ICM). It also completely ruptures the trophectoderm thereby minimizing the contamination of inner cell mass (ICM), thus ensuring the purity of inner cell mass (ICM).
  • REFERENCES
  • 1. Antinori S, Versaci C, Fuhrberg P et al (1994). Seventeen live birth after the use of erbium-yytrium aluminum garnet laser in the treatment of male factor infertility. Hum Reprod. 9: 1891-1896.
  • 2. Cohen J, Elsner C, Kort H et al (1990). Impairment of the hatching process following IVF in the human and improvement of implantation by assisting hatching using micromanipulation. Hum Reprod. 5: 7-13
  • 3. Depypere H T, McLaughlin K J, Seamark R F et al (1988). Comparison of zona cutting and zona drilling as techniques for assisted fertilization in the mouse. J. Reprod Fertil. 84: 205-211.
  • 4. Doetschman T, Williams P and Maeda N (1988) Establishment of hamster blastocyst derived embryonic stem (ES) cell. Developmental Biology 127: 224-227.
  • 5. Evans M J and Kaufman M H (1981). Establishment in culture of pluripotential cells from mouse embryo. Nature 292: 154-156.
  • 6. Evans M J, Notarianni E, Laurie S and Moor R M (1990) Derivation and preliminary characterization of pluripotent cell lines from porcine and bovine blastocyst. Theriogenology 33: 125-128.
  • 7. Feichtinger W, Strohmer H, Fuhrberg P et al (1992). Photoablation of oocyte zona pellucida by erbium-yag laser for in-vitro fertilization in severe male infertility. Lancet. 339, 811.
  • 8. Gordon J W (1988). Use of micromanipulation for increasing the efficiency of mammalian fertilization in vitro. Ann. N.Y. Acad. Sci. 541: 601-613.
  • 9. Gordon J W and Talansky B E (1986). Assisted fertilization by zona drilling: a mouse model for correction of oligospermia. J. Exp Zool. 239: 347-354.
  • 10. Germond M, Nocera D, Senn A. Rink K. et al (1995). Microdissection of mouse and human zona pellucida using 1.48 microns diode laser beam: efficacy and safety of the procedure. Fertil Steril. 64: 604-611.
  • 11. Germond M, Nocera D, Senn A, Rink A et al (1996). Improved fertilization and implantation rates after non-touch zona pellucida microdrilling of mouse oocytes with a 1.48 micron diode laser beam. Hum Reprod. 11: 1043-1048
  • 12. Giles J R, Yang X, Mark X and Foot R H (1993). Pluripotency of cultured rabbit inner cell mass cells detected by isozyme analysis and eye pigmentation of fetus following injection into blastocysts or morula. Molecular Reproduction and Development 36: 130-138.
  • 13. Graves K H and Moreadith R W (1993). Derivation and characterization of putative pluripotential embryonic stem cells from pre-implantation rabbit embryo. Molecular reproduction and Development 36: 424-433.
  • 14. Iannaccone P M, Taborn G U, Garton R L et al (1994). Pluripotent embryonic stem cells from the rat are capable of producing chimeras. Developmental Biology 163:288-292.
  • 15. Martin G R (1981) Isolation of pluripotent cell lines from early mouse embryos cultured in medium conditioned with teratocarcinoma stem cells. Proceeding of National Academy of Sciences USA 72: 1441-1445.
  • 16. Meinecke-Tillmann S and Meinecke B (1996). Isolation of ES like cell lines from ovine and caprine pre-implantation embryo. J Animal Breeding and Genetics 113: 413-426.
  • 17. Narula A, Taneja, Totey S M (1996) Morphological cells to trophectoderm inner cell mass of in vitro fertilized and parthenogenetically developed buffalo embryo: the effect of IGF-1. Mol. Reprod. Dev. 44(3):343-51.
  • 18. Neev J, Gonzales A, Lucciardi F et al (1993). Opening of the mouse zona pellucida by laser without a micromanipulator. Hum Reprod. 8: 939-944.
  • 19. Obruca A, Strohmer H, Sakkas D (1994). Use of laser in assisted fertilization and hatching. Hum Reprod. 9:1723-1726.
  • 20.Parikh F R, Kamat S A, Nadkarni S et al (1996). Assisted hatching in an in vitro fertilization program. J Reprod Fertil Suppl 50: 121-125
  • 21. Reubinoff B E, Per M F, Fong C Y, Trounson A and Bongso A (2000) Embryonic stem cell lines from human blastocysts: Somatic differentiation in vivo. Nat Biotechnol. 18:299-304.
  • 22. Rink K, Delacretaz G, Salathe R P et al (1994). Proceedings SPIE. 2134A, 412-422.
  • 23. Rink K, Delacretaz G, Salathe R P et al (1996). Non-contact microdrilling of mouse zona pellucida with an objective delivered 1.48 microns diode laser. Lasers Surg Med. 18:52-62.
  • 24. Sukoyan M A, Golublitsa A N, Zhelezova A I et al (1992) Isolation and cultivation of blastocyst derived stem cell lines from American Mink. Molecular Reproduction and Development 33: 418-431.
  • 25. Tarin J J and Handyside A H (1993). Embryo biopsy strategies for preimplantation diagnosis. Fertil Steril 59:943-952.
  • 26. Thomson J A, Itskovitz-Eldor J, Shapiro S S. et al. (1998). Embryonic stem cell lines derived from human blastocyst. Science 282: 1145-1147.
  • 27. Thomson J A, Kalishman J, Golos T G et al (1996). Pluripotent cell line derived from common marmoset blastocyst. Biology of Reproduction. 55: 254-259
  • OBJECTS OF THE INVENTION
  • 1. It is an object of the present invention, to develop a process of isolation of inner cell mass, using laser ablation technique, without undergoing the cumbersome procedure of immunosurgery.
  • 2. It is another object of the present invention to isolate ICM using laser ablation technique without using any animal generated antibodies and sera, thereby preventing the possibility of transmission of animal organism to human and thus can be used on commercial scale.
  • 3. It is another object of the present invention to isolate inner cell mass (ICM) from blastocyst stage of a mammalian embryo using a non-contact diode laser.
  • 4. It is another object of the present invention to isolate inner cell mass (ICM) by simple, shorter and easily feasible way without affecting/destroying the inner cell mass (ICM).
  • 5. It is still another object of the present invention to ensure the purity of inner cell mass (ICM) by rupturing completely trophectoderm thereby minimising the contamination of inner cell mass (ICM).
  • 6. It is still another object of the present invention to isolate inner cell mass (ICM) of high yield and purity as compared to the inner cell mass (ICM) isolated by the conventional methods.
  • These and other objects of the invention will become more readily apparent from the ensuing description.
  • DETAILS OF INVENTION
  • The present invention relates to isolation of inner cell mass, using laser ablation of zona pellucida (ZP) and trophectoderm (TE) and aspiration of inner cell mass for establishing embryonic stem cell lines. In the present invention, the non contact diode laser used is highly accurate and reliable tool for cellular microsurgery. The system incorporates the latest in fiber optic technology to provide the most compact laser system currently available. The 1.48 .mu.m diode non-contact Saturn Laser System is mounted/implanted via the epifluorescence port to inverted microscope fitted with micromanipulators. A pilot laser is used to target the main ablation laser and a series of LEDs inform the user when the laser is primed and is ready to fire. A two-second-operation window is used to reduce the possibility of accidentally firing the laser. The spot diameter of the laser can be varied according to the hole size required.
  • Couples undergoing in vitro fertilization (IVF) treatment voluntarily donate surplus human embryos. These embryos are used for research purposes after taking the written, voluntary consent from these couples. In the present invention, blastocyst stage embryos are taken for the isolation of inner cell mass. The blastocyst is placed in a 35 mm petridish in a 50 micro litre droplets of Ca++/Mg++ free embryo biopsy medium and is covered with mineral oil. The micromanipulator is set up to perform the embryo biopsy procedure. The blastocyst is placed in embryo biopsy medium and the petridish containing the blastocyst is placed on the heating stage of the microscope. The blastocyst is positioned at the center of the field. The blastocyst is immobilized on to the holding pipette in such a way that the inner cell mass is at 3 o'clock position. The zona pellucida and trophectoderm close to inner cell mass is positioned on the aiming spot of the laser beam. A small portion of zona pellucida and trophectoderm is laser ablated. Biopsy pipette is then gently inserted through the hole in the zona pellucida and trophectoderm and the inner cell mass is gently aspirated. After isolation of the complete inner cell mass, the cells are given several washes with embryonic stem cell (ESC) medium. The cells are then plated on to feeder layer with embryonic stem cell medium for establishing embryonic stem cell lines. The embryonic stem cells were then characterized for cell surface markers such as SSEA-1, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, OCT-4 and alkaline phosphatase. The embryonic stem cell lines are also karyotyped.
  • a) Development of Blastocyst in Vitro:
  • Institutional Ethics Committee approval has been obtained before initiation of this study. Prior written consent was taken from individual donor for the donation of surplus embryos for this study after completion of infertility treatment.
  • Protocol generally used for infertility patients for obtaining viable embryo is as follows:
  • The ovarian superovulation began with gnRH agonist analog suppression daily starting in the mid-luteal phase and administered in doses of 500-900 mgs for about 9-12 days. Ovarian stimulation was started after adequate ovarian suppression with human menopausal gonadotropins (hMG) or recombinant follicle stimulating hormone (FSH) (Gonal-F, Recagon) in appropriate doses depending on the age and ovarian volume. The dose was also adjusted as necessary to produce controlled ovarian stimulation. Serum beta-estradiol (E2) measurements were carried out as required. Vaginal ultrasound was performed daily from cycle day 7 onward. Human Chorionic gonadotropin 5000-10000 I.U. was administered when three or more follicles were at least 17 mm in largest diameter. Transvaginal aspiration was performed 34-36 h later. Oocytes were then subjected to intracytoplasmic sperm injection.
  • A glass holding pipette 40-60 .mu.m in diameter was used to secure the egg. Motile sperm were placed in a drop of polyvinyl pyrolidone (PVP) solution and overlaid with mineral oil. An injection needle with an outer diameter of roughly 5-6 μm and inner diameter 3-4 μm was used to pierce the zona pellucida at about 3 o'clock position. The selected spermatozoon was immobilized by cutting the tail with the injection micropipette. The holding pipette secured the oocyte and spermatozoon was injected directly into the center of the oocyte.
  • Oocytes were checked after 16-18 hours of culture for fertilization. At this point the fertilized oocyte had pro-nuclei (also called one cell embryo). One-cell embryos were then transferred into pre-equilibrated fresh ISM-1 medium and incubated at 37° C. in a 5% CO2 in air. The next day embryos were transferred into ISM-2 medium. Every alternate day embryos were transferred into fresh ISM-2 medium. From day 5 onward embryos were checked for the blastocyst development. After the treatment is over, the surplus blastocysts were donated by the couples for this research work.
  • b) Setting up of the Laser:
  • The present invention relates to describing a unique method for inner cell mass isolation for establishment of embryonic stem cells using the non-contact diode laser. The laser is highly accurate and reliable tool for cellular microsurgery. The system incorporates the latest in fiber optic technology to provide the most compact laser system currently available. The 1.48 μm diode non-contact Saturn Laser System was mounted via the epifluorescence port to Zeiss inverted microscope fitted with micromanipulators.
  • A pilot laser was used to target the main ablation laser and a series of LED's, inform the user when the laser is primed and ready to discharge the laser beam. A two-second-operation window was used to reduce the possibility of accidentally firing the laser. The spot diameter of the laser can be varied according, to the ablation size required.
  • c) Laser Ablation and Isolation of inner Cell Mass.
  • The blastocyst stage embryo was individually placed in a 50 μl drop of biopsy medium (Ca++/Mg++ free) in a 35-mm petri dish. The embryo was immobilized on to the holding pipette in such a way that the inner cell mass remained at 3 o'clock position and the zona pellucida and trophectoderm close to inner cell mass positioned on the aiming spot. A continuous 1.48 μm diode laser was used to aperture the Zona Pellucida (ZP), which is a glycoprotein layer protecting the oocyte. At this wavelength, the hole was induced by a local thermo-dissolution of the glycoprotein matrix. Once the zona pellucida was dissolved, trophectoderm cells were ablated by giving 3 pulses to cause photolysis. After ablation of both zona pellucida and trophectoderm, the aspiration pipette was introduced through laser-ablated hole and ICM was removed by gentle aspiration, having an internal diameter of 30-35 microns.
  • d) Culturing of Human Embryonic Stem Cells (hESC)
  • Prior to culturing, the aspirated ICM was washed thoroughly in ES medium, which medium was found to be preferred for isolation of embryonic stem cell lines. Given below is the procedure when the invention was carried out using feeder layer. In this process, the inner cell mass was cultured in 96 well plate in the presence of mouse inactivated embryonic fibroblast feeder layer. Embryonic fibroblast feeder layer was preferably obtained from 12.5 to 13.5 day old C57BL/6 mice or C57L/6XSJL F-1 mice or out bred CD1 mice or from human amniotic fluid-and used as a feeder layer. Embryonic fibroblast feeder layer was inactivated by gamma irradiation (3500 rads). The mouse embryonic fibroblast feeder layer was cultured on 0.5% gelatin coated plate with ES medium consisting of Dulbecco's modified Eagle's medium without Sodium pyruvate with high glucose contain (70-90%), Fetal bovine serum (10-30%), beta-mercaptoethanol (0.1 mM), non-essential amino acids (1%), L-Glutamine 2 mM, basic fibroblast growth factor (4 ng/ml). Inner cell mass was then plated on mouse inactivated embryonic fibroblast. After 4-7 days, ICM derived masses were removed from outgrowth with sterile fire polished pipette and were dissociated mechanically and plated on fresh feeder cells. Further dissociation was carried out with 0.5% trypsin-EDTA supplemented with 1% chicken serum.
  • Established cell lines were karyotyped and characterized for several surface markers such as SSEA-1, SSEA-3, SSEA-4, OCT-4, Alkaline phosphatase, TRA-1-81, TRA-1-60 as described by Thomson et al., (1998), Reubinoff et al., (2000).
  • EXAMPLES
  • The following examples are intended to illustrate the invention but do not limit the scope thereof.
  • Example 1
  • Total of 24 blastocyst stage human embryos were used for the isolation of inner cell mass. Embryos were washed several times in blastocyst culture medium (ISM-2 medium, Medicult, Denmark). Individual blastocyst was then placed in the 50 μl drop of Ca++/Mg++ free embryo biopsy medium (EB 10 medium, Scandinavian). Micro drops were covered with mineral oil. Micromanipulator was set up. A glass holding pipette with outer diameter 75 μm and inner diameter 15 μm was used to secure the embryo. Biopsy pipette with an outer diameter of roughly 49 μm and inner diameter 35 μm was used for aspiration of inner cell mass. A pilot laser was used to target the main ablation laser. Embryo was immobilized on to the holding pipette in such a way that inner cell mass remained at 3 o'clock position and the zona pellucida and trophectoderm close to inner cell mass positioned to the aiming spot. The hole was induced by a local thermo-dissolution of the zona. Trophectoderm cells were ablated by giving 3 pulses to cause photolysis. After ablation of both the zona pellucida and trophectoderm, the biopsy pipette was introduced through laser ablated hole and inner cell mass was removed. Inner cell mass was then washed several times in ES medium and placed in 96 well dish in the presence or absence of feeder cells. The following data is presented in the tabular form.
    TABLE 1
    Summary of hESC lines developed using Laser ablation Technique
    of the present invention with the use of mouse feeder cells.
    With mouse feeder cells
    No. of blastocysts used Total inner cell No. of No. of ES cell lines
    for laser ablation mass removed ICM used established
    24 18 14 4
  • Similarly, an experiment was conducted with conventional method of isolation of inner cell mass i.e. using immunosurgery and may be reported as follows:
  • Example 2
  • The objective was to determine efficiency of isolation of inner cell mass with conventional method, i.e. immunosurgery, and compared with newly invented laser ablated method.
  • Twenty-one blastocyst stage human embryos were used for isolation of inner cell mass. Embryos were washed several times with blastocyst culture medium (ISM-2 medium) and followed by ES medium. Individual blastocyst stage embryo was then placed in 50 μl microdrops of 1:50 anti-human antibody (Sigma) for 30 minutes at 37° C. and 5% CO2 in air. Blastocyst stage embryos were then washed four times after incubation with ES medium. Blastocysts were then again placed in 50 μl of microdrops of guinea pig complement at the concentration of 1:10 for 10 minutes at 37° C. and 5% CO2 in air. After incubation blastocyst stage embryos were washed several times in ES medium using fine bore glass pipette in order to remove trophectoderm. Isolated inner cell mass was then washed with ES medium and cultured in 96 well plate in the presence or absence of feeder cells. Data are presented in the table:
    TABLE 2
    Summary of hESC lines developed using immunosurgery
    with/without the use of mouse feeder cells.
    With mouse feeder Without mouse
    No. of cells feeder cells
    blastocyst Total No. No. No.
    used inner of of ES of No. of ES
    for laser cell ICM cell lines ICM cell lines
    ablation mass removed used established used established
    21 14 12 3 2 0
  • Although the isolation of inner cell mass using both the methods did not show any significant difference, however, of isolation of inner cell mass by laser ablation has distinct advantage. This method will eliminate the use of antibodies and sera of animal origin. Isolation of inner cell mass by laser ablation method can be further cultured in the presence or absence of feeder layer. However, culturing of inner cell mass in a feeder free condition will further eliminate the possibilities of contamination of ES cell lines with animal viruses or bacteria and can be commercially utilized for human transplantation studies. In the current experiments, efforts were made to establish ES cell line in the absence of feeder cells.
  • A preferred embodiment of the invention is illustrated in the accompanying drawings.
  • FIG. 1(a) to 1(g) of the present invention, pertains to the isolation of inner cell mass (ICM) from the blastocyst of one embryo and FIG. 2(a) to 2(g) pertains to the isolation of inner cell mass (ICM) from the blastocyst of another embryo. FIGS. 3, 4, and 5 pertains to culturing of ICM on feeder cells at different stages.
  • FIG. 1 (a) is a scanned image of human blastocyst, secured with glass holding pipette such that the ICM is at 3 o'clock position.
  • FIG. 1 (b) is a scanned image wherein part of zona pellucida and trophectoderm ablated with laser (arrow).
  • FIG. 1 (c) is a scanned image of aspiration pippette close to the blastocyst following zona and trophectoderm ablation.
  • FIG. 1 (d) is a scanned image of beginning of aspiration of ICM with aspiration pipette.
  • FIG. 1 (e) is a scanned image of large portion of ICM in the aspiration pipette during aspiration process.
  • FIG. 1 (f) is a scanned image of the ICM after removing from the blastocyst.
  • FIG. 1 (g) is a scanned image of the remaining trophectoderm and zona pellucida remaining after ICM isolation.
  • FIG. 2 (a) is a scanned image of another human blastocyst, secured with glass holding pipette such that the ICM is at 3 o'clock position.
  • FIG. 2 (b) is a scanned image of slight protrusion of inner cell mass after zona and trophectoderm is laser ablated.
  • FIG. 2 (c) is a scanned image of the aspiration pipette being position close to the ICM after ablating the zona and neighboring trophectoderm cells with laser.
  • FIG. 2 (d) is a scanned image of ICM being aspirated with the aspiration pipette by gentle suction.
  • FIG. 2 (e) is a scanned image of large portion of ICM in the aspiration pipette.
  • FIG. 2 (f) is a scanned image of the ICM after removing from the blastocyst.
  • FIG. 2 (g) is a scanned image of the trophectoderm and zona pellucida left after the isolation of ICM from the blastocyst.
  • FIG. 3 (a) is a scanned image of isolated inner cell mass in culture seeded on primary mouse embryonic fibroblast feeder cells (day 3).
  • FIG. 3 (b) is a scanned image of isolated inner cell mass in culture on primary mouse embryonic fibroblast feeder cells (day 7).
  • FIG. 4 is a scanned image of isolated ICM in culture on the primary mouse embryonic fibroblast feeder cells (day 5) another embryo.
  • FIG. 5 is a scanned image of embryonic stem cell line derived from inner cell mass isolated by laser ablation method.
  • One skilled in the art will appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned therein above. The instant invention has been shown and described herein in what is considered to be the most practical and preferred embodiment. It is recognized that departures may be made from within the scope of the invention. It is to be understood that the invention is not limited to the particulars disclosed and extends to all equivalents within the scope of the scope of the claims.

Claims (23)

1-20. (canceled)
21. A method of establishing a cell line from the inner cell mass of a human blastocyst, comprising:
(a) isolating a blastocyst having a zona pellucida, a trophectoderm, and an inner cell mass;
(b) creating an aperture in the blastocyst by laser ablation;
(c) isolating cells from the inner cell mass from the blastocyst through the aperture; and
(d) culturing the cells to establish a cell line, wherein the cells are cultured under feeder free conditions.
22. The method of claim 21, wherein the aperture is through the zona pellucida.
23. The method of claim 21, wherein the aperture is through the zona pellucida and the trophectoderm.
24. The method of claim 21, wherein the laser ablation is achieved using a non contact diode laser.
25. The method of claim 24, wherein the non contact diode laser is a continuous 1.48 μm diode laser.
26. The method of claim 21, wherein cells from the inner cell mass are isolated by aspiration.
27. The method of claim 21, wherein isolating cells from the inner cell mass is carried out in the absence of animal generated antibodies and sera.
28. The method of claim 21, further comprising a micromanipulator system comprising a microscope with a heating stage, a holding pipette, an aspiration pipette, and an air syringe, wherein the isolated blastocyst of step (a) is placed on the heating stage, the micromanipulator system is adjusted so that the blastocyst is at the center of the microscope field, and the blastocyst is secured with the holding pipette by suction through the air syringe, so that the inner cell mass is opposite the holding pipette.
29. The method of claim 21, wherein the feeder free conditions comprise an extracellular matrix.
30. The method of claim 29, wherein the feeder free conditions further comprise conditioned medium.
31. The method of claim 21, wherein the isolated blastocyst is the product of in vitro fertilization.
32. A method of establishing a human embryonic stem cell line, comprising:
(a) isolating a human blastocyst comprising an inner cell mass;
(b) creating an aperture in the blastocyst by laser ablation;
(c) isolating cells from the inner cell mass of the blastocyst through the aperture; and
(d) culturing the cells under feeder free conditions to obtain an isolated human embryonic stem cell line.
33. The method of claim 32, wherein the aperture is through the zona pellucida and the trophectoderm.
34. The method of claim 32, wherein the laser ablation is achieved using a non contact diode laser.
35. The method of claim 32, wherein the cells of the inner cell mass are cultured to produce inner cell mass-derived cell masses.
36. The method of claim 35, wherein the inner cell mass-derived cell masses are dissociated and re-plated on an extracellular matrix.
37. The method of claim 32, wherein cells of the inner cell mass are isolated by aspiration.
38. The method of claim 32, wherein the human embryonic stem cell line is established in the absence of animal generated antibodies and sera.
39. The method of claim 32, wherein the feeder free condition comprises plating the cells of the inner cell mass on an extracellular matrix.
40. A method of establishing a human embryonic stem cell line, comprising:
(a) isolating cells of an inner cell mass from a blastocyst by creating an aperture in the blastocyst by laser ablation and removing cells of the inner cell mass from the blastocyst through the aperture;
(b) culturing the cells of the inner cell mass to produce inner cell mass derived masses; and
(c) culturing the inner cell mass derived masses under feeder free conditions to produce an isolated human embryonic stem cell line.
41. The method of claim 40, wherein the feeder free conditions comprise an extracellular matrix.
42. The method of claim 40, further comprising mechanically dissociating the inner cell mass derived masses of step (b) and re-plating the mechanically dissociated cells of the inner cell mass derived masses under feeder free conditions.
US11/939,397 2001-08-23 2007-11-13 Isolation of Inner Cell Mass for the Establishment of Human Embryonic Stem Cell (hESC) Lines Abandoned US20080064099A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/939,397 US20080064099A1 (en) 2001-08-23 2007-11-13 Isolation of Inner Cell Mass for the Establishment of Human Embryonic Stem Cell (hESC) Lines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31432301P 2001-08-23 2001-08-23
US10/226,711 US7294508B2 (en) 2001-08-23 2002-08-23 Isolation of inner cell mass for the establishment of human embryonic stem cell (hESC) lines
US11/939,397 US20080064099A1 (en) 2001-08-23 2007-11-13 Isolation of Inner Cell Mass for the Establishment of Human Embryonic Stem Cell (hESC) Lines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/226,711 Division US7294508B2 (en) 2001-08-23 2002-08-23 Isolation of inner cell mass for the establishment of human embryonic stem cell (hESC) lines

Publications (1)

Publication Number Publication Date
US20080064099A1 true US20080064099A1 (en) 2008-03-13

Family

ID=23219502

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/226,711 Expired - Fee Related US7294508B2 (en) 2001-08-23 2002-08-23 Isolation of inner cell mass for the establishment of human embryonic stem cell (hESC) lines
US11/939,397 Abandoned US20080064099A1 (en) 2001-08-23 2007-11-13 Isolation of Inner Cell Mass for the Establishment of Human Embryonic Stem Cell (hESC) Lines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/226,711 Expired - Fee Related US7294508B2 (en) 2001-08-23 2002-08-23 Isolation of inner cell mass for the establishment of human embryonic stem cell (hESC) lines

Country Status (13)

Country Link
US (2) US7294508B2 (en)
EP (1) EP1421181A1 (en)
JP (3) JP2005514004A (en)
KR (1) KR20040030161A (en)
CN (1) CN1545549A (en)
AU (1) AU2002334378B2 (en)
BR (1) BR0212098A (en)
CA (1) CA2458362A1 (en)
IL (2) IL160351A0 (en)
RU (1) RU2291703C2 (en)
SG (1) SG172471A1 (en)
WO (1) WO2003018783A1 (en)
ZA (1) ZA200304132B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US9999785B2 (en) 2014-05-30 2018-06-19 Dr. Todd Frank Ovokaitys Method and system for generation and use of activated stem cells
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2022226647A1 (en) * 2021-04-27 2022-11-03 The Governing Council Of The University Of Toronto Systems and methods for detection and 3d imaging of cell junctions of blastocysts and other biological structures

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090004A1 (en) * 2003-01-16 2005-04-28 Sayre Chauncey B. Stem cell maturation for all tissue lines
US20050170506A1 (en) * 2002-01-16 2005-08-04 Primegen Biotech Llc Therapeutic reprogramming, hybrid stem cells and maturation
US20030134422A1 (en) * 2002-01-16 2003-07-17 Sayre Chauncey Bigelow Stem cell maturation for all tissue lines
RU2345133C2 (en) * 2003-03-12 2009-01-27 Релайанс Лайф Сайенсиз Пвт. Лтд. Production of terminal-differentiated dofaminnergic neurones from embrionic human founder cells
US7820439B2 (en) * 2003-09-03 2010-10-26 Reliance Life Sciences Pvt Ltd. In vitro generation of GABAergic neurons from pluripotent stem cells
US20050272149A1 (en) 2004-06-02 2005-12-08 Life & Brain Gmbh Therapeutic delivery of adenosine into a tissue
DE102004062184B4 (en) 2004-12-23 2013-08-01 Wolfgang Würfel Embryo-preserving production of pluripotent embryonic stem cells, stem cells thus obtained and use thereof
US7642091B2 (en) 2005-02-24 2010-01-05 Jau-Nan Lee Human trophoblast stem cells and use thereof
JP2009517001A (en) 2005-05-17 2009-04-30 リライアンス ライフ サイエンシーズ プライベイト リミテッド Construction of human embryonic stem cell lines using mammalian cells
US20060269985A1 (en) * 2005-05-31 2006-11-30 Yasuhiko Kitayama Method for constructing array blocks, and tissue punching instrument and tissue blocks used therefor
CN101233226B (en) * 2005-06-22 2017-08-11 阿斯特利亚斯生物治疗股份公司 The suspension culture of human embryo stem cell
CA2624728A1 (en) * 2005-10-07 2007-04-19 Cellartis Ab A method for obtaining a xeno-free hbs cell line
WO2007079533A1 (en) * 2006-01-10 2007-07-19 South Eastern Sydney And Illawarra Area Health Service Method for establishing and proliferating human esc by co-culturing with allogeneic feeder cells in serum-free media
EP2245141B1 (en) 2008-01-18 2018-03-14 Regents of the University of Minnesota Stem cell aggregates and methods for making and using
WO2010114193A1 (en) 2009-03-29 2010-10-07 Kim Chang-Hyun Isolation method for inner cell masses and method for preparing embryonic stem cell lines using the same
SG10201913618WA (en) 2009-07-21 2020-03-30 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
CN104962512B (en) 2009-07-21 2022-09-09 Abt控股公司 Use of stem cells for reducing leukocyte extravasation
JP5115762B2 (en) * 2010-02-12 2013-01-09 有機合成薬品工業株式会社 Process for producing 4-formylpiperidine acetal derivative
SG183497A1 (en) 2010-02-25 2012-09-27 Abt Holding Co Modulation of macrophage activation
SG10201913904PA (en) 2010-02-25 2020-03-30 Abt Holding Co Modulation of angiogenesis
WO2011143415A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
WO2011158125A2 (en) 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
WO2012027474A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Non-static suspension culture of cell aggregates
EP2625577B1 (en) 2010-10-08 2019-06-26 Terumo BCT, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
EP2640403A4 (en) 2010-11-15 2014-04-23 Jua-Nan Lee Generation of neural stem cells from human trophoblast stem cells
WO2012071393A2 (en) * 2010-11-23 2012-05-31 The New York Stem Cell Foundation Method for producing pluripotent stem cells
EP2673358B1 (en) 2011-02-08 2019-01-09 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
US20120308531A1 (en) 2011-06-06 2012-12-06 ReGenesys BVBA Expansion of Stem Cells in Hollow Fiber Bioreactors
GB201119335D0 (en) 2011-11-09 2011-12-21 Univ Leuven Kath Hepatitis virus infectable stem cells
CN102600507B (en) * 2012-03-08 2014-08-20 天津大学 Cell culture support frame material and preparation method of cell culture support frame material
CA3137404A1 (en) 2012-11-30 2014-06-05 Accelerated Biosciences Corp. Pancreatic progenitor cells expressing betatrophin and insulin
CA2909267C (en) 2013-04-12 2022-10-25 Saverio LA FRANCESCA Improving organs for transplantation
DK2992088T3 (en) 2013-04-30 2019-11-11 Univ Leuven Kath CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES
JP6633522B2 (en) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド Cell growth in bioreactors
CN107208054B (en) 2014-11-26 2021-09-17 艾克塞利瑞提德生物技术公司 Induced hepatocytes and uses thereof
CN104982419B (en) * 2015-07-29 2017-01-11 广西壮族自治区水牛研究所 Buffalo embryo freezing method in combination with laser membrane rupture
US20200325449A1 (en) 2016-06-02 2020-10-15 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
CA3138884A1 (en) 2019-05-06 2020-11-12 Accelerated Biosciences Corp. Precursory regulatory cytotrophoblast cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642048B2 (en) * 2000-01-11 2003-11-04 Geron Corporation Conditioned media for propagating human pluripotent stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JP2002529070A (en) * 1998-11-09 2002-09-10 モナシュ・ユニヴァーシティ Embryonic stem cells
JP4889902B2 (en) 2000-03-14 2012-03-07 イーエス・セル・インターナショナル・プライヴェート・リミテッド Method for producing human neural progenitor cells from human embryonic stem (hES) cells, method for producing neurons using the method, method for producing oligodendrocytes or astrocytes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642048B2 (en) * 2000-01-11 2003-11-04 Geron Corporation Conditioned media for propagating human pluripotent stem cells

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US11739366B2 (en) 2010-07-23 2023-08-29 Astellas Institute For Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US9999785B2 (en) 2014-05-30 2018-06-19 Dr. Todd Frank Ovokaitys Method and system for generation and use of activated stem cells
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10907144B2 (en) 2014-05-30 2021-02-02 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US11905510B2 (en) 2014-05-30 2024-02-20 Todd Frank Ovokaitys Methods and systems for activating cells to treat aging
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
US10865157B2 (en) 2014-06-06 2020-12-15 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2022226647A1 (en) * 2021-04-27 2022-11-03 The Governing Council Of The University Of Toronto Systems and methods for detection and 3d imaging of cell junctions of blastocysts and other biological structures

Also Published As

Publication number Publication date
EP1421181A1 (en) 2004-05-26
JP2008194055A (en) 2008-08-28
US7294508B2 (en) 2007-11-13
RU2004108209A (en) 2005-04-20
JP2008099706A (en) 2008-05-01
ZA200304132B (en) 2004-07-19
JP2005514004A (en) 2005-05-19
WO2003018783A1 (en) 2003-03-06
IL160351A0 (en) 2004-07-25
CN1545549A (en) 2004-11-10
RU2291703C2 (en) 2007-01-20
CA2458362A1 (en) 2003-03-06
BR0212098A (en) 2004-08-03
SG172471A1 (en) 2011-07-28
IL160351A (en) 2009-11-18
AU2002334378B2 (en) 2008-02-28
US20030104616A1 (en) 2003-06-05
KR20040030161A (en) 2004-04-08
US20070048864A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
US7294508B2 (en) Isolation of inner cell mass for the establishment of human embryonic stem cell (hESC) lines
AU2002334378A1 (en) Isolation of inner cell mass for the establishment of human embryonic stem cell (hESC) lines
Stein et al. Assisted hatching by partial zona dissection of human pre-embryos in patients with recurrent implantation failure after in vitro fertilization
Wang et al. Functional analysis of activation of porcine oocytes by spermatozoa, calcium ionophore, and electrical pulse
Rawlins et al. Microsurgical enucleation of tripronuclear human zygotes
Yang et al. Intracytoplasmic sperm injection improving embryo quality: comparison of the sibling oocytes of non-male-factor couples
Nagy et al. Removal of lysed blastomeres from frozen–thawed embryos improves implantation and pregnancy rates in frozen embryo transfer cycles
Petersen et al. Laser-assisted hatching of cryopreserved—thawed embryos by thinning one quarter of the zona
Lanzendorf et al. A randomized, prospective study comparing laser-assisted hatching and assisted hatching using acidified medium
Schöpper et al. Possible applications of lasers in assisted reproductive technologies
Ebner et al. Successful birth after laser assisted immobilization of spermatozoa before intracytoplasmic injection
US7083977B2 (en) Monkey-origin embryonic stem cells
US20120142107A1 (en) Method and system for somatic cell nuclear transfer
Veiga et al. Assisted hatching
Cohen et al. Micromanipulation in clinical management of fertility disorders
Rodríguez et al. Derivation of clinical-grade human embryonic stem cells
Anderson et al. Fertilization, embryonic development and pregnancy losses with intracytoplasmic sperm injection for surgically-retrieved spermatozoa
Cohen et al. Gamete and embryo micromanipulation for infertility treatment
JP5014535B2 (en) Cynomolgus monkey-derived embryonic stem cells
Campbell et al. Epiblast cell number and primary embryonic stem cell colony generation are increased by culture of cleavage stage embryos in insulin
Letterie Assisted hatching: Rationale, technique, and clinical outcomes
Veiga et al. Assisted hatching 12
Bui et al. Female Germline Stem Cells: Potential Applications in Reproductive Technology
RU2352637C1 (en) Method of obtaining of hybrid human stem cell
Gardner et al. Assisted hatching

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION